BACKGROUND: Sandwich chemotherapy as first postoperative treatment might cause resistance to ensuing irradiation. Simultaneous radiochemotherapy might prevent this. PATIENTS AND METHODS: Twenty-nine children with high-grade glioma were treated from 1997-1999. The median age was 11.1 years. Tumor locations included: cerebral cortex 12, deep cerebral locations 11, cerebellum 3, spinal cord 3. Pons was excluded. Total (n = 9), subtotal (n = 3) and partial (n = 9) tumor resection or biopsy (n = 7) were followed by radiochemotherapy: fractionated radiation (1.8 Gyld up to 59.4 Gy) was given simultaneously with two cycles of chemotherapy (cisplatin 20 mg/m2/d x 5d, etoposide 100 mg/m2/d x 3d, and cisplatin, etoposide, ifosfamide: 1.5 g/m2/d). The data of a previous protocol (Cancer 89: 2131-7, 2000) in the same population were used as controls. RESULTS: Early progressive disease (PD 2 out of 25 patients) was significantly less frequent as compared to the control group (p = 0.031). The toxicity appeared tolerable.
BACKGROUND: Sandwich chemotherapy as first postoperative treatment might cause resistance to ensuing irradiation. Simultaneous radiochemotherapy might prevent this. PATIENTS AND METHODS: Twenty-nine children with high-grade glioma were treated from 1997-1999. The median age was 11.1 years. Tumor locations included: cerebral cortex 12, deep cerebral locations 11, cerebellum 3, spinal cord 3. Pons was excluded. Total (n = 9), subtotal (n = 3) and partial (n = 9) tumor resection or biopsy (n = 7) were followed by radiochemotherapy: fractionated radiation (1.8 Gyld up to 59.4 Gy) was given simultaneously with two cycles of chemotherapy (cisplatin 20 mg/m2/d x 5d, etoposide 100 mg/m2/d x 3d, and cisplatin, etoposide, ifosfamide: 1.5 g/m2/d). The data of a previous protocol (Cancer 89: 2131-7, 2000) in the same population were used as controls. RESULTS: Early progressive disease (PD 2 out of 25 patients) was significantly less frequent as compared to the control group (p = 0.031). The toxicity appeared tolerable.
Authors: Johannes E A Wolff; Sabine Wagner; Christiane Reinert; Astrid Gnekow; R-D Kortmann; Joachim Kühl; Stefaan W Van Gool Journal: J Neurooncol Date: 2006-04-28 Impact factor: 4.130
Authors: Johannes E A Wolff; Carl Friedrich Classen; Sabine Wagner; Rolf-Dieter Kortmann; Shana L Palla; Torsten Pietsch; Joachim Kühl; Astrid Gnekow; Christof M Kramm Journal: J Neurooncol Date: 2008-01-22 Impact factor: 4.130
Authors: Michael Karremann; Sandra Butenhoff; Ulrike Rausche; Torsten Pietsch; Johannes E A Wolff; Christof M Kramm Journal: Neuro Oncol Date: 2008-12-02 Impact factor: 12.300
Authors: Johannes E A Wolff; Christof Kramm; Rolf-Dieter Kortmann; Torsten Pietsch; Stefan Rutkowski; Norbert Jorch; Astrid Gnekow; Pablo Hernáiz Driever Journal: J Neurooncol Date: 2008-08-05 Impact factor: 4.130
Authors: Michael Karremann; Torsten Pietsch; Gisela Janssen; Christof M Kramm; Johannes E A Wolff Journal: J Neurooncol Date: 2008-11-29 Impact factor: 4.130
Authors: S Wagner; M Benesch; F Berthold; A K Gnekow; S Rutkowski; R Sträter; M Warmuth-Metz; R-D Kortmann; T Pietsch; J E A Wolff Journal: Br J Cancer Date: 2006-10-03 Impact factor: 7.640